**PISA Business Meeting – Monday March 13, 2017**

LaPlaya Resort, Naples, FL

**Members present**:

|  |  |  |
| --- | --- | --- |
| Paul von Autenried (BMS) [E1]Dominik Zimmerli (BI) [E2]Georgia Papathomas (J&J) [E3]Mike Carlin (Abbvie) [Treasurer]Andreas Mueller (Novartis)Matt Pammer (AZ) | Daniel Lebeau (GSK)Aarti Shah (Lilly)Steve Winawer (Sanofi)Daniel Klaus (BI)Ulf Surig (Abbott) | Jeff Hamilton (Pfizer)Pragati Masur (Biogen)Sandy Arcuri (Biogen)Andy Newsom (CSL Behring)Rama Kondru (J&J) |

**Agenda** (attached).

**Treasurers report** (attached).

**Officer succession**: Georgia Papathomas becomes E1. Daniel Kraus replaces Dominik Zimmerli as E2. Aarti Shah becomes E3.

**Topics of further interest**

1. IT Cost recovery mechanisms > table attached.
	1. capital accounting treatment?
2. IT role in analytics > table attached
3. IT role in digital > table attached
	1. AZ
	2. Novartis definition of digital to distinguish
4. cyber security challenges
5. Global workforce
	1. degree of outsourcing
	2. Captive centers
	3. Employees vs Contractors
6. Application Portfolio Rationalization
7. rate of change toward liquid workforce

**Suggestions for next year**:

East coast, Florida, Miami

Sunday night -> Tuesday, prior to Easter holiday

3 external presenters

Lightning Round, 15 min per member, plus agenda time for focus topics of deeper interest

Survey of the members prior to the meeting might help identify those topics in advance.

IT role in Digital

|  |  |  |  |
| --- | --- | --- | --- |
|  | Digital Operations | Digital Relationship | Digital Business |
| Abbvie |  |  |  |
| Abbott |  |  |  |
| AZ | IT | IT+Marketing | shared |
| Biogen |  |  |  |
| BI |  |  |  |
| BMS | IT | IT+Marketing | IT+head of Strategy |
| CSL Behring |  |  |  |
| GSK, main problem is prioritization | IT=how, business=whatSmarter employees | IT=how, business=what | IT=how, business=whatNew lines of business |
| J&J | IT | business | IT |
| Novartis |  |  |  |
| Pfizer |  |  |  |
| Sanofi |  |  |  |
| Lilly |  |  |  |

IT role in Analytics

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | IT Leads | IT enables | Centralized outside of IT | Federated across Company | Centralized within IT |
| Abbvie | X | XX |  | XXX |  |
| Abbott | X | XX |  | XXX |  |
| AZ | X | XX |  | XXX |  |
| Biogen | X | XX | ??? | XXX |  |
| BI | X | XX |  | XXX |  |
| BMS | X | XX | XXX |  |  |
| CSL Behring | XXX |  |  |  | XXX |
| GSK | XX | X |  | X | X |
| J&J |  |  |  |  |  |
| Novartis | XX | X |  | X | X |
| Pfizer | X | XX |  | XXX |  |
| Sanofi |  | XXX |  | XXX |  |
| Lilly | X | XX |  | XXX |  |
|  |  |  |  |  |  |

IT cost recovery

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Full cost recovery | Partial cost recovery (e.g. projects) | Zero cost recovery | Software capitalization |
| Abbvie |  | XXX |  | >$100K, 5-7 yrs |
| Abbott |  | XXX |  |  |
| AZ |  | XXX |  | >$5M, 5 yrs |
| Biogen |  | XXX |  | No threshold |
| BI |  |  | XXX | Software but not labor |
| BMS |  |  | XXX | >$1M, 5 yrs |
| CSL Behring |  | XXX |  | Based on life of asset >3 yrs, typ 5-7 years |
| GSK |  | X | XX |  |
| J&J |  | XXX |  | >$100K, 5-7 yrs |
| Novartis | XXX |  |  | >$5M, 5 yrs |
| Pfizer |  | X | XX |  |
| Sanofi | XX | X |  | >$500K, 5-7 yrs |
| Lilly |  | X | XX |  |
|  |  |  |  |  |